Abbott Laboratories (ABT) Q3 2024 Earnings Call Transcript
Welcome to Abbott's third quarter 2024 earnings conference call. [Operator instructions] This call is being recorded by Abbott. With the exception of any participants questions asked during the question-and-answer session,
Abbott Labs beats Q3 sales and earnings expectations, raises full-year outlook
Abbott Laboratories on Wednesday reported better-than-expected third-quarter earnings and sales, boosted by strength in the company’s medical-devices business.
Abbott Laboratories posts Q3 beat, raises profit forecast
Abbott Laboratories (ABT) shares tick into positive territory in Wednesday's pre-market trading on its third quarter earnings beat driven by strong demand for the company's medical devices. Morning Brief Hosts Seana Smith and Brad Smith break down what investors need to know.
Abbott Laboratories Q3 Profit Increases, Beats Estimates
Abbott Laboratories (ABT) revealed earnings for its third quarter that increased from the same period last year and beat the Street
Abbott: Q3 Earnings Snapshot
On a per-share basis, the Abbott Park, Illinois-based company said it had profit of 94 cents. Earnings, adjusted for non-recurring costs, came to $1.21 per share. The results topped Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.20 per share.
Abbott bumps up profit forecast on strong medical device sales
Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for quarterly earnings on strong demand for its glucose-monitoring products and other medical devices.
Abbott raises earnings outlook as MedTech, Pharma drive Q3 beat
Abbott Laboratories (NYSE:ABT) increased its full-year earnings guidance on Tuesday after its financials for Q3 2024 exceeded Wall Street's forecasts, thanks mainly to the strength in its Pharma and MedTech segments.
Abbott Stock Gains on Q3 Earnings Beat, Margins Expand
Abbott Laboratories ABT reported third-quarter 2024 adjusted earnings per share (EPS) of $1.21, which beat the Zacks Consensus Estimate by 0.8%. The figure also improved 6.1% from the prior-year quarter’s level.
ABT Earnings: Strong Medical Device Sales Help Abbott Beat Q3 Estimates
Abbott ($ABT) reported better-than-expected third-quarter results on Wednesday. The medical devices and healthcare company’s sales increased by
Benzinga.com1d
Abbott Laboratories' Q3 Earnings: Revenue And EPS Beat, Company Says Well-Positioned To Achieve Upper End Of Annual Forecast
Abbott's Q3 sales reached $10.64B, beating the consensus of $10.55B ... beating the analyst estimates of $1.20. Also Read ...
Abbott Laboratories: It's No Longer A Buy For Now
Abbott Laboratories is showing strong growth potential with rising sales and EPS, though slightly overvalued. See why we are ...
High-Quality Abbott Stock: Corporate Growth That Pays You to Own It
Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...
Travis Steed Reiterates Buy Rating on Abbott Laboratories Amid Promising Growth and Under-Ownership Potential
Travis Steed, an analyst from Bank of America Securities, reiterated the Buy rating on Abbott Laboratories (ABT – Research Report). The ...
Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event
Abbott Laboratories' Q3 earnings and topline growth largely expected to be in line with the Q2 trend. Find out whether ABT ...
Zacks.com on MSN3d
Abbott's Q3 Earnings Release Coming Up, EPD Business in Focus
ABT's Neuromodulation growth is expected to have been driven by strong demand in international markets for the Eterna ...
pharmaphorum3d
A history of Abbott and AbbVie
This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...